Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MGCND00EP1 in Children and Adolescents With Resistant Epilepsies
NCT04406948Phase 2Withdrawn
- Sponsor
- MGC Pharmaceuticals
- Start
- May 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in epilepsy comparing MGCND00EP1 with Placebo (2 arms). Primary endpoints: Proportion of patients showing a >50% reduction in frequency of seizures at 12 weeks and Change in number of epileptic seizures at 16 weeks. Planned start May 2024; status: withdrawn.
02
Drugs
CannEpil
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT04406948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04406948.